Identification of a Homozygous Variant in the CYP21A2 Gene by Next-Generation Sequencing Analysis of Circulating Cell-Free Fetal DNA
Authors:
- Nadia PetrilloNPNadia Petrillo
- Simone MarcellaSMSimone Marcella
- Roberto SiricaRSRoberto Sirica
- Monica IannielloMIMonica Ianniello
- Raffaella RuggieroRRRaffaella Ruggiero
- Alessio MoriAMAlessio Mori
- Rosa CastielloRCRosa Castiello
- Cristina RamiroCRCristina Ramiro
- Rossana D’angeloRDRossana D’angelo
- Giuliano PennacchioGPGiuliano Pennacchio
- Ermanno BarlettaEBErmanno Barletta
- Roberto PassaroRPRoberto Passaro
Open Access
Abstract
Background/Objectives: Congenital adrenal hyperplasia (CAH) is an autosomal recessive disorder caused by mutations in the CYP21A2 gene associated with 21-hydroxylase deficiency and increased levels of adrenal androgens. Affected females are at risk of ambiguous genitalia, while affected males show sexual precocity. Here, we present a case of a newborn female patient, characterized by ambiguous genitalia and previously identified as low risk for common aneuploidies by non-invasive prenatal testing (NIPT). Methods: We performed a NIPT, which showed a 46, XX genotype, confirmed by karyotype on the newborn’s DNA extracted lymphocytes. For clinical suspicion of CAH, we performed reverse dot blot and Multiple Ligation-dependent Probe Amplification (MLPA) of the CYP21A2 gene on the patients and her parents’ DNA. Then, we performed on mother’s plasma NGS analysis with an in-house developed panel of genes for monogenic diseases, including the CYP21A2 gene. Results: Reverse dot blot and MLPA detected the presence of the c.290-13A/C>G (I2 splice) mutation in heterozygosity in the parents and in homozygosity in the child, respectively. NGS detected the c.290-13A/C>G (I2splice) mutation in cell-free fetal DNA (cfDNA) in mother’s plasma with a variant allele frequency (VAF) of 67% with a fetal fraction (FF) of 5%. This latter suggests the presence of the variant both in the mother and in newborn cfDNA. Conclusions: The study reinforces the hypothesis that cfDNA can be used to identify point mutations, small insertions and/or deletions for the diagnosis of monogenic diseases, reducing the number of invasive tests and the risk of early miscarriages. Early detection of mutations in genes causing sexual development disorders could make it possible to start therapy in the womb.Keywords
This publication has 40 references indexed in Scilit:
- Noninvasive prenatal screening in a pregnant woman with a history of stem cell transplant from a male donor: A case report and literature reviewMolecular Genetics & Genomic Medicine, 2024
- The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartumReviews in Endocrine and Metabolic Disorders, 2022
- Low fetal fraction in obese women at first trimester cell‐free DNA based prenatal screening is not accompanied by differences in total cell‐free DNAPrenatal Diagnosis, 2021
- Non-invasive prenatal diagnosis and screening for monogenic disordersEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2020
- Noninvasive prenatal paternity testing by means of SNP‐based targeted sequencingPrenatal Diagnosis, 2019
- Genetics of congenital adrenal hyperplasia and genotype-phenotype correlationFertility and Sterility, 2019
- What parameters affect knee function in patients with untreated cartilage defects: baseline data from the German Cartilage RegistryInternational Orthopaedics, 2018
- cfDNA screening and diagnosis of monogenic disorders – where are we heading?Prenatal Diagnosis, 2018
- Gestational age and maternal weight effects on fetal cell‐free DNA in maternal plasmaPrenatal Diagnosis, 2013
- Genetics of congenital adrenal hyperplasiaBest Practice & Research Clinical Endocrinology & Metabolism, 2009